A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C
A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C
A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov models in which hypothetical cohorts of patients progressed through a series of health states characteristic of the natural history of CHC. The studies analyzed various regimens of PEG-IFN alfa-2b plus RBV including stopping rules for different genotypes, and fixed or weight-based dosing of RBV. In all studies, PEG-IFN alfa-2b plus RBV was associated with favorable incremental cost-effectiveness ratios (ICERs) when compared with IFN plus RBV. Tailored treatment according to bodyweight dosing and circumscribed treatment for different genotypes improves ICERs further. Further cost-effectiveness analyses should consider the impact of antiviral treatment in subgroups of patients including those co-infected with HIV, hemophiliacs and patients who are retreated following previous treatment failure, where data are available.
577-595
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Jones, Jeremy
270b303b-6bad-4be7-8ea0-63d0e8015c91
December 2007
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Jones, Jeremy
270b303b-6bad-4be7-8ea0-63d0e8015c91
Shepherd, Jonathan and Jones, Jeremy
(2007)
A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C.
Expert Review of Pharmacoeconomics & Outcomes Research, 7 (6), .
(doi:10.1586/14737167.7.6.577).
(PMID:20528320)
Abstract
A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov models in which hypothetical cohorts of patients progressed through a series of health states characteristic of the natural history of CHC. The studies analyzed various regimens of PEG-IFN alfa-2b plus RBV including stopping rules for different genotypes, and fixed or weight-based dosing of RBV. In all studies, PEG-IFN alfa-2b plus RBV was associated with favorable incremental cost-effectiveness ratios (ICERs) when compared with IFN plus RBV. Tailored treatment according to bodyweight dosing and circumscribed treatment for different genotypes improves ICERs further. Further cost-effectiveness analyses should consider the impact of antiviral treatment in subgroups of patients including those co-infected with HIV, hemophiliacs and patients who are retreated following previous treatment failure, where data are available.
This record has no associated files available for download.
More information
Published date: December 2007
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 345710
URI: http://eprints.soton.ac.uk/id/eprint/345710
ISSN: 1473-7167
PURE UUID: 470355f9-25e9-4896-80aa-64e6b97c3217
Catalogue record
Date deposited: 28 Nov 2012 15:53
Last modified: 15 Mar 2024 02:48
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
